Fulcrum’s Phase 3 for old GSK drug fails, stock sinks

Ful­crum Ther­a­peu­tics re­port­ed a Phase 3 fail Thurs­day morn­ing, send­ing its stock plum­met­ing.

The biotech said that a study test­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.